Table 1.
Groups | PBS | TNFα | Ozoralizumab-TNFα IC1 | Ozoralizumab-TNFα IC2 | Adalimumab-TNFα ICs | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Number of animals | 3 | 3 | 3 | 3 | 3 | ||||||||||
Grade | – | ± | + | – | ± | + | – | ± | + | – | ± | + | – | ± | + |
Skin (injection site) | |||||||||||||||
Subcutaneous neutrophil infiltration | 3 | 0 | 0 | 2 | 1 | 0 | 3 | 0 | 0 | 3 | 0 | 0 | 0 | 1 | 2 |
-, None/Negligible, ±, Minimal/Very slight, +, Mild/Slight.
ICs, immune complexes; PBS, phosphate-buffered saline; TNF, tumor necrosis factor.